Evidence map›Paper›PMID 35917337›Full record

ArticlePloS one2022

Life-course socioeconomic conditions, multimorbidity and polypharmacy in older adults: A retrospective cohort study.

Katharina Tabea Jungo, Boris Cheval, Stefan Sieber, Bernadette Wilhelmina Antonia van der Linden, Andreas Ihle, Cristian Carmeli, Arnaud Chiolero, Sven Streit, Stéphane Cullati

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Polypharmacy Is Associated With Slow Gait Speed and Recurrent Falls in Older People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Katharina Tabea JungoInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.ORCID 0000-0002-1782-1345
Boris ChevalSwiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland.
Stefan SieberSwiss NCCR "LIVES: Overcoming Vulnerability: Life Course Perspectives", University of Geneva, Geneva, Switzerland.
Bernadette Wilhelmina Antonia van der LindenCenter for the Interdisciplinary Study of Gerontology and Vulnerability, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-4815-2121
Andreas IhleSwiss NCCR "LIVES: Overcoming Vulnerability: Life Course Perspectives", University of Geneva, Geneva, Switzerland.
Cristian CarmeliPopulation Health Laboratory, #PopHealthLab, University of Fribourg, Fribourg, Switzerland.
Arnaud ChioleroInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Sven StreitInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Stéphane CullatiPopulation Health Laboratory, #PopHealthLab, University of Fribourg, Fribourg, Switzerland.
University of Geneva · CHUniversity of Bern · CHUniversity of Fribourg · CH

Funding

NIA NIH HHS HHSN271201300071C
6 · The paper itself

Abstract

Socioeconomic conditions across the life course may contribute to differences in multimorbidity and polypharmacy in old age. However, whether the risk of multimorbidity changes during ageing and whether life-course socioeconomic conditions are associated with polypharmacy remain unclear. We investigated whether disadvantaged childhood socioeconomic conditions (CSCs) predict increased odds of multimorbidity and polypharmacy in older adults, whether CSCs remain associated when adjusting for adulthood socioeconomic conditions (ACSs), and whether CSCs and ACSs are associated cumulatively over the life course. We used data for 31,432 participants (multimorbidity cohort, mean [SD] age 66·2[9] years), and 21,794 participants (polypharmacy cohort, mean age 69·0[8.9] years) from the Survey of Health, Ageing, and Retirement in Europe (age range 50-96 years). We used mixed-effects logistic regression to assess the associations of CSCs, ASCs, and a life-course socioeconomic conditions score (0-8; 8, most advantaged) with multimorbidity (≥2 chronic conditions) and polypharmacy (≥5 drugs taken daily). We found an association between CSCs and multimorbidity (reference: most disadvantaged; disadvantaged: odds ratio (OR) = 0·79, 95% confidence interval (CI) 0·70-0·90; middle: OR = 0·60; 95%CI 0·53-0·68; advantaged: OR = 0·52, 95%CI 0·45-0·60, most advantaged: OR = 0·40, 95%CI 0·34-0·48) but not polypharmacy. This multimorbidity association was attenuated but remained significant after adjusting for ASCs. The life-course socioeconomic conditions score was associated with multimorbidity and polypharmacy. We did not find an association between CSCs, life-course socioeconomic conditions, and change in odds of multimorbidity and polypharmacy with ageing. Exposure to disadvantaged socioeconomic conditions in childhood or over the entire life-course could predict multimorbidity in older age.

Indexed as

Life Change EventsMultimorbidityAdultAgedAged, 80 and overCohort StudiesCross-Sectional StudiesHumansMiddle AgedRetrospective StudiesSocioeconomic Factors

Identifiers

PMID35917337
PMCPMC9345356
OpenAlexW4289525217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.